Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters
Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs
Handwipe Disclosing Method for Detecting the Presence of Lead
Novel malaria vaccine candidates comprising engineered nanoparticles
Using proteins derived from the malaria Plasmodium falciparum parasite, NIAID has developed three different nanoparticle platforms to serve as scaffolds for displaying multiple copies of malaria antigens in an organized, repetitive manner to enhance vaccine effectiveness. The first platform uses the pyridoxal 5’-phosphate (PLP) synthase protein to form a nanoparticle displaying 48 copies of up to 4 different proteins. The second platform uses the chaperone 60 (Cpn60), which can display 28 copies of up to 2 different proteins.
Human antibodies with anti-lymphocyte specificities and lytic activity
Antibody therapies that target human B cells are a promising way to treat diseases like B-cell cancers and autoimmune conditions like lupus and multiple sclerosis. Traditionally, these antibodies are made in animals and modified to resemble human antibodies to reduce immune rejection.
Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells
Regulatory T cells (Tregs) are immune cells that keep the immune system balanced and prevent autoimmunity. Tregs depend on a protein called Eos (Ikzf4) that helps turn genes on and off for their development and function, but until now, antibodies used to detect and study Eos were unreliable.
First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)
It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF-a and TGF-b; and 4) angiogenesis by activating transcription of VEGF.
Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon-gamma as a therapeutic agent for proliferative eye diseases.